

**A Dissertation on**  
**A CLINICAL STUDY OF CORRELATION OF**  
**BIOCHEMICAL INDICES INCLUDING**  
**HDL<sub>2</sub>/HDL<sub>3</sub> RATIO WITH DIABETIC**  
**RETINOPATHY SEVERITY STATUS**

**Submitted to**  
**THE TAMIL NADU Dr. M.G.R. MEDICAL UNIVERSITY**  
**CHENNAI**



**With fulfillment of the regulation**  
**for the award of the degree of**  
**M.S.. (OPHTHALMOLOGY)**  
**BRANCH-III**

**MADRAS MEDICAL COLLEGE**  
**CHENNAI-600008**  
**MARCH 2009**

## **CERTIFICATE**

This is to certify that **Dr. Anupam Yadava**, Post Graduate student in M.S Ophthalmology, at Regional Institute of Ophthalmology and Government Ophthalmic hospital attached to Madras Medical College, Chennai, carried out this dissertation on “**A STUDY OF CORRELATION OF BIOCHEMICAL INDICES INCLUDING HDL<sub>2</sub>/HDL<sub>3</sub> RATIO WITH DIABETIC RETINOPATHY SEVERITY STATUS**” under my direct guidance and supervision during the period from May 2006 to March 2009.

This dissertation is submitted to the TamilNadu Dr.MGR Medical University, Chennai in partial fulfillment of award of M.S. Degree in Ophthalmology.

**Prof. Dr. M.S. Rajarathinam**

Chief, Glaucoma Clinic

RIO - GOH,

Chennai - 8.

**Prof. Dr. M. Radhakrishnan**

Director & Superintendent,

RIO - GOH,

Chennai - 8.

**Prof.Dr. T. P. Kalanithi, M.D.,**

**Dean,**

**Madras Medical College, Chennai**

## DECLARATION

I, **Dr. Anupam Yadava**, solemnly declare that the dissertation titled **“A STUDY OF CORRELATION OF BIOCHEMICAL INDICES INCLUDING HDL<sub>2</sub>/HDL<sub>3</sub> RATIO WITH DIABETIC RETINOPATHY SEVERITY STATUS”** has been prepared by me. This is submitted to The Tamil Nadu Dr. M.G.R. Medical University, Chennai, in partial fulfillment of the requirement for the award of M.S. Ophthalmology, degree Examination to be held in March 2009.

Place: Chennai

Date:

## **ACKNOWLEDGEMENT**

I feel extremely grateful to **GOD** for granting me the wisdom to complete this dissertation.

First and foremost I would like to offer my sincere gratitude to the patients , without whose cooperation this dissertation would not have been possible.

I am thankful to **PROF. Dr. T.P. Kalanithi, M.D., DEAN, Madras Medical College** for allowing me to pursue my dissertation at the Regional Institute of Ophthalmology.

I convey my sincere thanks to **Prof. Dr. M. Radhakrishnan, M.S., D.O., Director and Superintendent, Regional Institute of Ophthalmology** for his support.

I express my gratitude to my past **Glaucoma Unit Chief Prof. Dr. V. Velayutham M.S.,D.O.**, and the present **Glaucoma Unit Chiefs Prof. Dr. M.S. Rajarathinam, M.S. , D.O. and Prof. Dr. K. Maragatham M.S., DO**, for their unwavering support .

I am extremely thankful to my unit **Assistant Professors, Dr. N. Jayanthi, M.S. D.O., Dr. Rajini, M.S. , Dr. Sharmila, M.S. , Dr. Muthiah M.S. ,** for their sincere and loving guidance.

My sincere thanks to **Prof. Dr. R. Chitra ,H.O.D. , Department of Bio-Chemistry, M.M.C. Chennai, and Bio-chemistry Lab technicians Mr. A. Ganesan, Mr. T. Francis, RIO-GOH** for carrying out the bio-chemical investigations.

## CONTENTS

| <b><u>PART- I</u></b>                                 | <b>PageNo.</b> |
|---|----------------|
| INTRODUCTION  | 7              |
| REVIEW OF LITERATURE                                  | 10             |
| DIABETIC RETINOPATHY PRVALENCE AND INCIDENCE          | 12             |
| SYSTEMIC FACTORS ASSOCIATED WITH DIABETIC RETINOPATHY | 13             |
| PATHOLOGY OF DIABETIC RETINOPATHY                     | 14             |
| CLASSIFICATION OF DIABETIC RETINOPATHY                | 19             |
| BIO-CHEMICAL ASPECTS IN DIABETIC RETINOPATHY          | 43             |
| <b><u>PART-II</u></b>                                 |                |
| AIM OF STUDY  | 53             |
| MATERIALS AND METHODS                                 | 53             |
| ANALYSIS AND DISCUSSION                               | 57             |
| SUMMARY   | 65             |
| CONCLUSIONS   | 69             |
| <b><u>PART-III</u></b>                                |                |
| BIBLIOGRAPHY  | 72             |
| PROFORMA  |                |
| MASTER CHART  |                |
| INDEX TO MASTER CHART                                 |                |
| ABBREVIATION  |                |
| LIST OF OPERATIONS PERFORMED                          |                |

## **INTRODUCTION**

Diabetes mellitus (DM) is a group of metabolic disorders that share the common phenotype of hyperglycemia caused by complex interaction of genetic and environmental factors and life style choices. Hyperglycemia can occur due to decreased insulin secretion, decreased glucose utilization and increased glucose production. The metabolic dysregulation associated with DM causes secondary pathophysiological changes in multiple organ systems. It's a leading cause of end stage renal disease, nontraumatic lower limb amputation and adult blindness.

DM is classified according to the pathogenic process that leads to hyperglycemia into two broad categories type 1 and type 2. In type 1 DM there is autoimmune destruction of beta cells in pancreas leading to insulin deficiency. Type 2 is characterized by varying degrees of insulin resistance, decrease in insulin production and increase in glucose production. Type 1 usually develops before the age of 30 years while type 2 develops with increasing age. (But 5-10% of cases diagnosed after 30 years of age have immune destruction of beta cells and type 2 can also occur in children especially obese adolescents). Approximately 10% of diabetic population has type 1 DM and majority belong to type 2.

Chronic complications of DM affect many organ systems. These can be classified as vascular and nonvascular complications. Vascular complications can be further classified as microvascular and macrovascular.

**Microvascular complications:**

- a. Diabetic retinopathy
- b. Nephropathy
- c. Neuropathy: Sensory, motor, autonomic.

**Macrovascular complications:**

- a. Coronary artery disease
- b. Peripheral vascular disease
- c. Cerebrovascular disease

**Nonvascular complications:**

- a. Gastrointestinal: Gastrointestinal paresis, diarrhea
- b. Genitourinary: Uropathy, sexual dysfunction
- c. Dermatological
- d. Infectious
- e. Cataract
- f. Glaucoma.

Microvascular complications are caused due to hyperglycemia and it is conclusively proven that if hyperglycemia is well controlled, these complications can be prevented or delayed.

Type 2 DM has a long asymptomatic period, so it can present with these complications.

Diabetic retinopathy (DR) is a highly specific vascular complication of both type 1 and type 2 diabetes mellitus.. After 20 years of diabetes, nearly all patients with type 1 diabetes and more than 60% of patients with type 2 diabetes have some degree of retinopathy.

DR goes through various stages before leading to visual loss. The first clinical signs are microaneurysms. Then slowly it progresses and leads to formation of new vessels in retina which can lead to sight threatening complications like vitreous haemorrhage.

In general, the progression of retinopathy is orderly, advancing from mild nonproliferative abnormalities, characterized by increased vascular permeability, to moderate and severe nonproliferative diabetic retinopathy (NPDR), characterized by vascular closure, to proliferative diabetic retinopathy (PDR), characterized by the growth of new blood vessels on the retina and posterior surface of the vitreous. The severity and progression of diabetic



retinopathy is affected by many factors. Duration of diabetes, glycosylated haemoglobin, type of treatment (insulin treatment versus non-insulin treatment), systolic and diastolic blood pressures and serum creatinine, showed a positive association with retinopathy while body mass index (BMI) showed an inverse association.

## **REVIEW OF LITERATURE**

Diabetic retinopathy is a microvascular complication of both type 1 & type 2 diabetes mellitus. In the eye its effects are seen predominantly in the retina. It causes loss of vision due to intraocular hemorrhage, tractional retinal detachment, clinically significant macular edema, and macular ischaemia. According to one study, yearly incidence of sight-threatening diabetic retinopathy in patients without retinopathy at baseline was 0.3% in the first year, rising to 1.8% in the fifth year, cumulative incidence at 5 years was 3.9%. Whereas for background diabetic retinopathy, rates of progression to sight-threatening diabetic retinopathy in 1 year was 5% and for preproliferative diabetic retinopathy was 15%. Diabetic retinopathy causes damage by formation of advanced glycosylation end products, increased metabolism via sorbitol pathway and more importantly increased metabolism via hexosamine pathway leading to increased production of various growth factors like vascular endothelial growth factor (VEGF).

According to 2004 WHO publication there are 171 million people worldwide who have diabetes mellitus and the figures are likely double by 2030. India has about 31.7 million diabetic patients ranking first in the world. This number is projected to increase to 79.4 million by 2030.

In the Chennai Urban Rural Epidemiology Study (CURES) eye study I, the prevalence of diabetic retinopathy was found to be 17.6%. Another similar study CURES-2 was done to study the association of serum lipids with diabetic retinopathy in urban South Indians—the Chennai Urban Rural Epidemiology Study (CURES) Eye Study—2.

In general, the progression of retinopathy is orderly, advancing from mild nonproliferative abnormalities, characterized by increased vascular permeability, to moderate and severe nonproliferative diabetic retinopathy (NPDR), characterized by vascular closure, to proliferative diabetic retinopathy (PDR), characterized by the growth of new blood vessels on the retina and posterior surface of the vitreous. These new vessels may cause intraocular bleeding or the gliosis associated with them may cause tractional retinal detachment leading to significant visual loss.

The Early Treatment Diabetic Retinopathy Study (ETDRS) classification given by the ETDRS group was a modified Airlie House classification of diabetic retinopathy which was also used in the Diabetic Retinopathy study (DRS). The seven standard photographic fields were used, and the original

standard colour nonsimultaneous stereoscopic photographs were retained. New photographs were added and some additional characteristics were described. The classification was more elaborative and was more standardized which allowed a very little chance of examiner bias. Thus it has gained worldwide acceptance and presently is a standard for classification of diabetic retinopathy. ETDRS was a multicentric, randomized clinical trial basically designed to evaluate argon laser photocoagulation and aspirin treatment in the management of patients with nonproliferative or early proliferative diabetic retinopathy. ETDRS classified diabetic retinopathy into mild, moderate, severe, very severe, early PDR and high risk PDR depending on the characteristic lesions seen.

### **DIABETIC RETINOPATHY PREVALENCE AND INCIDENCE**

Nearly 171 million people worldwide have diabetes. This figure is likely to double by 2030. India holds 31.7 million diabetic patients ranking first in the world. This number is projected to increase to 79.4 million by 2030.

In 2002 DR accounted for about 5% of world blindness amounting to almost 5 million blind. In India, prevalence of DR has been reported to range from 10.5% to 26.2%. It remains a leading cause of new blindness in developed and developing countries between the ages of 20 and 74 years. The increasing incidence of diabetes has caused DR to be included in the “priority list” as a part of “Vision 2020”.

Worldwide Diabetic retinopathy accounts for 5% of total blindness. In the Chennai Urban Rural Epidemiology Study (CURES) eye study I, the prevalence of diabetic retinopathy was found to be 17.6%. A 1996 report from Madurai revealed that of the 1863 new diabetic patients seen at a tertiary centre, 37% had overt diabetic retinopathy<sup>14</sup>. The increasing incidence of diabetes has caused diabetic retinopathy to be included in the priority list as part of vision 2020.


#### **SYSTEMIC FACTORS ASSOCIATED WITH DIABETIC RETINOPATHY**

1. One of these is puberty, whether because of the marked hormonal changes that occur at this time or for other reasons.
2. Elevated levels of IGFs may enhance the development of proliferative diabetic retinopathy, in particular the rapidly progressive, or “florid”, retinopathy that is occasionally seen in young people late in adolescent or in young adulthood.
3. Growth hormone and IGF-1 are probably permissive for the development of retinal neovascularization but are not directly causal.
4. Increased blood pressure and increased blood sugar levels increase the risk for the development and progression of diabetic retinopathy.
5. Unilateral narrowing of the internal carotid artery resulting from arteriosclerosis protected the ipsilateral eye from developing diabetic retinopathy.

## **PATHOLOGY OF DIABETIC RETINOPATHY**

Various mechanisms put forth for the pathogenesis of hyperglycemia induced damage are:

1. Formation of advanced glycosylation end products
2. Increased metabolism via sorbitol pathway
3. Increased metabolism via hexosamine pathway leading to increased formation of fructose 6 phosphate which leads to increased production of various growth factors like vascular endothelial growth factors (VEGF)



So one can postulate the following sequence of events in the pathogenesis of diabetic retinopathy:

- a. Hyperglycaemia with insufficient insulin causes an increased output of growth hormone.
- b. Elevated levels of growth hormone in the presence of reduced levels of insulin alter the hepatic cell synthesis of proteins causing a dysproteinemia.
- c. Elevated levels of fibrinogen and alpha 2 globulin increase red cell aggregation.
- d. Elevated levels of growth hormone associated with increased production of Von Willebrand factor and reduced levels of prostacyclin increase platelet aggregation.
- e. Hyperglycaemia impairs prostacyclin production by endothelial cells. Increased RBC and platelet aggregation impair haemodynamics in the microcirculation.
- g. Impaired blood flow in the microcirculation by a sluggish flow rate or microinfarction leads to hypoxia and ischaemia.
- h. Hypoxia and ischaemia probably cause diabetic retinopathy by the elaboration of a vasoformative factor which stimulates new vessels formation in the optic nerve region or the retina. Hypoxia and ischaemia can cause breakdown and leakage of retinal vessels, massively affect haemodynamic on


the nature, as well as transudation and exudation of the blood elements into the retinal structures.

### **PATHOLOGY:**

The histological picture of the vessels resemble the arteriosclerotic hypertensive picture. Terminal arterioles reveal hyaline thickening, coiling and narrowing of the lumen. The basement membrane of the capillaries is thickened and there is disappearance of intramural pericytes and endothelial cells. Ghost capillaries may be seen in diabetic retina which are occluded, functionless and these vessels have only thin basement membrane and possess neither pericytes nor endothelial cells. Adjacent to these capillaries normal functionless capillaries may also lose their intramural pericytes and endothelial cells and may be potential sites for saccular aneurysm. Adjacent to the distended and tortuous vessels are seen which might have developed to produce collateral circulation. In the beginning their walls are thin but later on get occluded by hyaline material. The haemorrhages are mostly confined to outer plexiform layer and Henle's fibre layer and exudates are formed by polymerization of the unsaturated fats. They are chemically CEROID-wax like material and are regarded as breakdown products of degenerated neuronal tissue. The soft exudates are also seen and result from capillary infarction.



**ETDRS classification of Diabetic Retinopathy**



### **ETDRS classification [1991]**

Diabetic retinopathy is broadly classified as NPDR & PDR. Diabetic macular edema can occur in NPDR as well as PDR.

**Mild NPDR-** is marked by atleast one retinal microaneurysm, but hemorrhages or microaneurysm or both are less than those in ETDRS standard photograph no. 2A. No other retinal lesions or abnormalities associated with diabetes is present. Those patients with mild NPDR have a 5% risk of progressing to PDR within 1 year and a 15% risk of progression to high risk PDR within 5 years


**Moderate NPDR-** is characterized by hemorrhage or microaneurysm greater than those pictures in ETDRS standard photograph no 2A. cotton wool spots, venous beeding, and IRMAs are definitely present to mild degree. The risk of progression to PDR within 1 year is 12-27% and the risk of progression to high risk PDR within 5 years is 33%.

**Severe NPDR-** based on the severity of hemorrhage or microaneurysm, IRMAs, and venous beeding is characterized by any one of the following lesions: H/Ma greater than standard photograph no 2A in 4 quadrants OR venous beeding in 2 or more quadrants OR IRMAs greater than standard photograph no 8A in atleast 1 quadrant. Clinically severe NPDR is diagnosed by applying the 4-2-1 rule. Eyes with severe NPDR have a 52% risk of developing PDR within 1 year and 60% risk of developing high risk PDR within 5 years


**Very severe NPDR-** have 2 or more lesions of severe NPDR but no frank neovascularisation. There is 75% risk of developing PDR within 1 year.

**PDR-** Diabetic retinopathy marked by new vessel growth on optic disc (NVD) or elsewhere (NVE) on retina or by fibrous tissue proliferation is designated PDR. Eyes with early PDR have a 75% risk of developing high risk PDR within 5 year period.

# NO DIABETIC RETINOPATHY




# MILD DIABETIC RETINOPATHY



# MILD DIABETIC RETINOPATHY



# MODERATE DIABETIC RETINOPATHY



# MODERATE DIABETIC RETINOPATHY






# SEVERE DIABETIC RETINOPATHY



# SEVERE DIABETIC RETINOPATHY



# PROLIFERATIVE DIABETIC RETINOPATHY




# PROLIFERATIVE DIABETIC RETINOPATHY




# PRERETINAL HEMORRHAGE



# PRERETINAL HEMORRHAGE



# VITREOUS HEMORRHAGE




# TRACTIONAL RETINAL DETACHMENT






# TRACTIONAL RETINAL DETACHMENT



# TRACTIONAL RETINAL DETACHMENT



ETDRS also defined the various lesions seen in DR. the various lesions seen are

## ***DEFINITIONS***

### ***Microaneurysms (MA)–***

A red spot that is less than 1/12 the diameter of an average optic disc, or 125µm in its longest dimension (approximately the width of an average major vein at the disc margin) and that has sharp margins is considered to be a microaneurysm. Any red spot equal to or greater than 125µm in its longest dimension is considered to be a hemorrhage unless features such as round shape, smooth margins, and a central light reflex suggest that it is probably a microaneurysm.

### ***Hemorrhages (H) and/ or microaneurysms (MA)-***

All punctate, blot, or linear hemorrhages and all microaneurysms (whether the color of venous blood or paler, and with or without a recognizable wall) are included. Microaneurysms that appear as white dots with no blood visible in a central lumen are graded as hard exudates. Hemorrhages that are clearly preretinal are excluded. The grading is based on the area of retina covered by hemorrhages and/or microaneurysms, using standard photographs 1,2A and 2B for comparison.

### ***Hard exudates –***

Hard exudates are small white or yellowish-white deposits with sharp margins. Often they have a slightly waxy or glistening appearance. They are usually located in the outer layers of the retina, but may be more superficial, particularly when retinal thickening (edema) is present. Hard exudates may be arranged as individual dots, as confluent patches, or in partial or complete rings surrounding prominent microaneurysms or zones of retinal edema. The grading of hard exudates is based on the area of retina involved, using standard photographs 3,4 and 5 for comparison.

### ***Soft exudates –***

Soft exudates are localized superficial swellings in the nerve fiber layer. They are round or oval in shape, white, pale yellow-white, or grayish-white in color, and have ill-defined (feathery) edges, frequently with striations parallel to the nerve fibers. The grading is based on the area of retina involved, using standard photographs 8A and 5.

### ***Intraretinal microvascular abnormalities (IRMA)-***

Tortuous Intraretinal vascular segments, varying in caliber from barely visible to 31µm (approximately one fourth the width of a major vein at the disc margin) or occasionally larger, are the abnormalities considered in this category. Punctate microaneurysms in the retina and new vessels located on the surface of the retina are excluded. The grading is based on the area of the retina covered by IRMA, using standard photographs 8A and 8B.

### ***Venous abnormalities-***

In the ETDRS, three abnormalities that were combined in the DRS grading protocol are assessed separately: (a) venous beading, (b) venous narrowing, and (c) venous loops and/or reduplication. Venous sheathing and perivenous exudates are graded as in the DRS. Diffuse increase in venous caliber is not graded, because it is considered too difficult to evaluate consistently. Abnormalities within one half disc diameter (DD) of the disc margin are ignored.

### ***Venous beading-***

Localized increases in venous caliber, which sometimes resemble a string of beads and are typical of diabetic retinopathy, are the abnormalities assessed.

The grade is based on the total length of vein involved and the severity of beading, using standard photographs 6A and 6B for comparison.

***Venous narrowing-***

Localized narrowing of venous caliber is the abnormality considered. The total length of all narrowed segments within the field being graded is estimated and compared with the width of an average major vein at the disc margin (considered to be 125 $\mu$ m) and the diameter of an average disc.

***Venous loops and/or reduplication-***

A venous loop is an abrupt, curving deviation of a vein from its normal path. Reduplication of a vein is the dilation of a pre-existing channel or the proliferation of a new channel of similar caliber adjacent to the original vein. The grading is based on the caliber of the vein involved.

***Venous sheathing-***

White lines along one or both sides of the venous blood column (sheathing) and/or complete opacification of the venous wall (white threads) are the abnormalities graded. The total length of vein having either appearance is assessed, as with venous narrowing.

### ***Perivenous exudates-***

Hard exudates occurring immediately adjacent to one or both sides of retinal veins, simulating venous sheathing, are classified as perivenous exudates and graded separately. The total length of vein involved is assessed.

### ***Arteriolar abnormalities-***

Abnormalities within  $\frac{1}{2}$  DD of the disc margin are ignored

### **Arteriolar narrowing-**

Localized irregularities in arteriolar caliber are the abnormalities graded. Because it is considered too difficult to grade consistently, generalized narrowing is not evaluated, except to indicate narrowing so extensive that the arterioles and white threads are excluded when grading arteriolar narrowing. The grading is based on the length of arteriolar segments involved, using standard photographs 11 and 7.

### ***Arteriolar sheathing-***

Arteriolar walls that are partially opaque (a ribbon of red blood can still be seen with white lines on one or both sides of it) or completely opaque (no visible red blood column), are the abnormalities graded. The total length of arteriole that is either partially or fully opaque is assessed, using as cut points on the grading scale  $125\mu\text{m}$  and standard photographs 5 and 7.

### **New vessels -**

New vessels that are clearly on the surface of the retina (that is, not within the retina) or further forward in the vitreous cavity are considered to be new vessels elsewhere (NVE), except for those on the disc or within 1 DD of its margin (or in the vitreous anterior to this area), which are designated new vessels of the disc (NVD). However, if new vessels located mostly elsewhere extend into the area between  $\frac{1}{2}$  and 1 DD from the disc margin, and no other new vessels are present closer to or on the disc, all new vessels are included in the NVE category. These same criteria are used to distinguish between fibrous proliferations elsewhere (FPE) and fibrous proliferations of the disc (FPD). The grading is based on the area of retina covered by the new vessels, using as cut points on the grading scale  $\frac{1}{2}$  disc area (DA) and the NVE in standard photograph 7.

### ***Preretinal hemorrhage-***

Both boat-shaped hemorrhages with a fluid level and round, oval, or linear patches of the hemorrhage just anterior to the retina or under its internal limiting membrane are included. Hemorrhage on the surface of detached retina is also considered to be preretinal hemorrhage. The grading is based on the area



of retina covered by hemorrhage, using standard photographs 9 and 13 and the area of one half of the field for comparison.

### *Vitreous hemorrhage-*

Hemorrhage further forward in the vitreous cavity than pre retinal hemorrhage (PRH), including hemorrhage on or within fibrovascular proliferations, is considered to be vitreous hemorrhage (VH) .

The United Kingdom Prospective Diabetes study (UKPDS) was a landmark trial in NIDDM. It was a multicentric, randomised control trial. Both eyes of 2964 patients were studied. It concluded that increased blood pressure and increase fasting plasma glucose was associated with increased severity of retinopathy. Other conclusions derived were that retinopathy was more prevalent in men than women, body mass index (BMI) was inversely related to severity of retinopathy in women but not in men. High density lipoproteins (HDL) which has a protective role in atherosclerotic diseases was found to have inverse relationship with severity of retinopathy in men, i.e. higher HDL levels were associated with increased severity of retinopathy in men. But this was not so in women .

The Wisconsin Epidemiologic study of Diabetic Retinopathy which include 634 patient with IDDM also concluded that progression of retinopathy is more in males, in those having higher glycosylated hemoglobin and higher diastolic blood pressure at baseline .

### **BIO-CHEMICAL ASPECTS IN DIABETIC RETINOPATHY**

Diabetes occurs essentially in two forms: type 1, *formerly known as juvenile-onset diabetes (or type I); and type 2, which was once called mature-onset diabetes (or type II)*. Although the mechanisms for each vary, both forms involve an inability of glucose to enter certain classes of cells in the body that are dependent upon insulin-activated, transport protein systems.

**TYPE 1 DIABETES :** Type 1 diabetes was formerly called “juvenile diabetes” since it typically becomes manifest by age 20. However, it is now known that this form can occur after that age. Type 1 was also known as “insulin dependent diabetes” since its patients require periodic insulin injections. Again ,however patients with type 2 diabetes sometimes also require insulin injections. The immediate cause of type 1 is usually an autoimmune destruction of the b-cells of the pancreas that synthesize insulin. In addition to its role in glucose uptake , insulin signals the initiation of many other cell metabolic functions : amino acid uptake , glycolysis, formation of glycogen , and lipid synthesis as well as the

synthesis of proteins , DNA, and RNA. One can say that insulin is vital hormone since it communicates the continuation of cell nutrition and growth overall. However, the uptake of glucose remains as one of its most important functions.

The destruction of the b-cells of the pancreas , as mentioned above , appears to be an autoimmune phenomenon. There is a strong genetic component to the appearance of this form of diabetes, which is associated with the chromosome 6 genes for the *human leukocyte antigens* (HLA). Wildman and Medeiros(2000), describe these proteins , made by their respective genes, as critical for distinguishing between host and foreign cells. Because of the loss of insulin , high levels of glucose remain in the circulating blood long after the consumption of a meal. For this reason , type 1 diabetes has also been known as insulin dependent diabetes mellitus (IDDM).

It is important to understand that those cells that depend on insulin (those that have GLUT-4 transport proteins) become starved for nourishment while other cells , not dependent on insulin , become exposed to higher than normal cytoplasmic levels of glucose . This is to say that some cells have decreased nutrition while other cells are actually exposed to toxic levels of glucose. Cells that are particularly insulin dependent are muscle cells (cardiac, skeletal , and smooth) as well as adipose (fat ) cells (McGilvery, Goldstein, 1983) and *cells of blood vessel walls* ( Koschinsky, 1988). Among the cells

which are not insulin dependent are liver cells , nerve cells, red blood cells , bone cells, and *lens fiber cells* of the eye. This is why the enzyme aldose reductase is activated within lens fiber cells of the eye. This is why the enzyme aldose reductase is activated within lens fiber cells in the diabetic state.

In diabetes, particularly type 1, the insulin dependent cells alter their metabolism in pathological (i.e., abnormal ) ways in order to compensate for their lack of glucose . In muscle cells, for example , it is common in the diabetic state to accelerate the breakdown of aminoacids in order to obtain acetyl CoA as a precursor for ATP production. This occurs at the expense of muscle proteins in the body. In muscle cells, for example, it is common in the diabetic state to accelerate the breakdown of aminoacids in order to release fatty acids back into the bloodstream. These fatty acids are taken up by the liver to produce acetyl CoA for the same purpose of synthesizing ATP. However, in this case , not only are the stores of lipid reduced , but there is also a production of toxic intermediates from excessive fatty acid breakdown. These toxic intermediates are known as *ketone bodies*. Most ketone bodies (acetoacetate and B-Hydroxybutyrate) are sufficiently acidic to lower blood pH to dangerously low levels. This could occur to the point at which the patient might become comatose and, if untreated, could expire due to complications such as severe dehydration , respiratory distress, cerebral edema, and thromboembolism. Of

course, this represents an extreme of untreated type 1 diabetes or, in some cases, where insulin therapy management is very difficult.

High circulating levels of glucose can also bind to proteins both extracellularly and intracellularly (in those cells that do not have GLUT-4 transport proteins). The binding of glucose to proteins is known as glycation. Glycation is a slow reaction that proceeds through many steps. It is important to note that the reaction is permanent, meaning that when glucose levels are lowered the binding of glucose to the protein does not dissociate. Rather the reaction continues and produces more complex forms that result in the denaturation of the protein in what is known as the *Maillard reaction* (Berman, 1991). Finally, it should be noted that glucose in high concentrations has been proposed to cause DNA damage (Morita et al, 1985). However, Schleicher et al (2001), have indicated that only  $1 \times 10^{-5}\%$  of the guanine nucleotides of DNA would be expected to react with a glucose derivative in the diabetic state. This is a negligible amount.

**TYPE 2 DIABETES:** In type 2 diabetes formerly known as noninsulin dependent diabetes mellitus (NIDDM), there is *either* an insufficient number of functional insulin receptors on the plasma membranes of insulin dependent cells or the receptors, in normal amounts, fail to promote sufficient glucose uptake (Mathews, van Holde, 1990; Martin et al, 1985). The phenomenon of insufficient response to normal amounts of insulin is called *insulin resistance*.

In addition, patients with this disease also exhibit a somewhat decreased level of secreted insulin for unknown reasons. This insulin deficiency, however, does not often require insulin therapy. The cause(s) of type 2 diabetes remain vague (Wildman, Medeiros, 2000).

One causative attribute has been the association of this disease with obesity. How this occurs is not certain, but some evidence is available. For example, enlarged adipocytes (fat cells) secrete a protein known as *tumour necrosis factor-alpha* that has been shown to inhibit insulin receptor autophosphorylation.

A characteristic of type 2 diabetes is that the associated hyperglycemia tends to develop more slowly than with type 1 and is of a milder degree. Ketoacidosis, in untreated type 2 diabetics, occurs much less often and then it is usually associated with physiological stress such as an infection. Returning to the problem of insulin resistance, one may point to not only the insulin receptor protein, but also to any of the proteins associated with the cascade from the receptor to the placement of GLUT-4 molecules at the cell plasma membrane (Pessin, Saltiel, 2000). This means that any number of proteins may contribute to the resistance. Numerous data support this to indicate many possible causes of the disease and emphasizes the difficulties of trying to comprehend how this disease can manifest itself. In addition to the effect of fat cells on the insulin receptor, investigations have shown that knocking out the

gene for the *insulin substrate proteins* (insulin receptor substrates) in mice can produce insulin resistance as well as cause a decreased b-cell production of insulin in the pancreas(Kulkarni et al , 1999). The next protein in the cascade is phosphatidylinositol 3-kinase (PI3-K). Although PI3-K activity is necessary for the ultimate transport of GLUT-4 to the plasma membranes of insulin dependent cells (Chez, Corvera,1999) , its activity is not sufficient to carry out the transport. This means that additional mechanisms are involved(Pessin, Saltiel,2000) and, clearly , more work will be necessary to unravel the causes of insulin resistance. In spite of these uncertainties , a controlled diet coupled with exercise is often sufficient to manage type 2 diabetes.

**The Diabetic Retina:** The retina is vulnerable to diabetes due to deterioration that occurs to its blood vessels in a condition known as *diabetic retinopathy*. This is similar to diabetic blood vessel damage that also occurs to other parts of the body such as the kidneys , brain , and limbs. Essentially , in the retina pericytes are destroyed while the lumen of the vessel becomes blocked due to vessel swelling as the basement membranes thicken (Apple et al, 1988). As vessel pathology develops, haemorrhages and retinal detachment follow. The terminal result of these events is loss of vision in parts or all of the retina. Shedding light on a biochemical mechanism by which this damage occurs has proven to be a Pandora's box. As the box is opened, out pops the familiar enzyme *aldose reductase* and its role of removing excessively toxic amounts of

glucose from within cells such as blood vessel endothelial cells. Again, the problem of the generation of osmotic sorbitol arises. The problem ( the presence of large amounts of high osmotic, cell destroying sorbitol) and the solution (development of an effective inhibitor for aldose reductase ) are seen as logical exercise. However , other previously unknown participants emerge from the Pandora's box: *protein kinase C (PKC)*; *mitogen-activated protein kinase (MAPK)*; *protein glycation*; and *oxidative stress* (Tomlinson, 2000). The complications to understanding that are generated by these other substances mechanisms are, nonetheless, now seen as more important in the retina compared to the lens osmotic hypothesis. This is so since aldose reductase inhibitors do not seem to have any significant effect on the prevention of blood vessel degeneration in the retina. What roles might these other substances and mechanisms play?

In 1996 , King reported that high levels of glucose cause an increase in *diacylglycerol(DAG)*, a phospholipid precursor that is synthesized from glyceraldehydes 3-phosphate and dihydroxyacetone phosphate. The latter two substances are generated in the E-M pathway from glucose. DAG stimulates the activity of protein kinase C (PKC), an enzyme that acts as a part of a hormone cascade system at cell surfaces . PKC, as part of its many physiological functions, increases both blood vessel permeability and the excessive synthesis of blood vessel membranes. One of the features of diabetic blood vessels is their



“leakiness” (permeability) and their thickening with the synthesis of basement membranes. In a more recent publication . Park et al(2000), indicate that PKC causes the induction of the synthesis of the protein *endothelin-1(ET-1)*. This protein is responsible for increased blood vessel permeability as well as its thickening . similar effects may also be made through the activation of *mitogen activated protein (MAP) kinase*, an enzyme that translocates into the nucleus of the cell and affects many different cell functions *via* phosphorylation (Lodish et al ,2000).

Another effect of diabetes that arises from the Pandora’s box is the binding of glucose to proteins (glycation). In higher glucose concentrations , this occurs initially by what is known as the “Amadori rearrangement” of an initial Schiff base (aldimine) formation and is a *ketimine*. These protein-carbohydrate conjugates seem to occur in a number of extracellular proteins as well as the intracellular proteins of noninsulin dependent cells (Cohen, 1986). Such early stage complexes are exemplified by the existence of glycated hemoglobin (HbA1c) in the blood. HbA1c can actually be used to assay how well blood glucose control is being maintained in a diabetic (Williams, Pickup, 1999). Among those proteins known to be bound by glucose are collagen , crystallins, and enzymes such as NaK-ATPase, as well as hemoglobin.

Unfortunately, the initially formed protein-glucose ketimines may continue to react with time to form somewhat complex, permanent and

generally undefined, *advanced glycation end-products (AGEs)* as reported by Brownlee (1996). Among these AGEs, one has recently been described as an imidazole-crosslinked protein. AGEs produce a variety of effects including : (1) binding to receptors on vascular endothelial cells to produce a blockage in the vessel ; (2) a leakage of the vessel itself; (3) vessel dilation; (4) vessel thickening (Rudnicka. Birch, 2000) and cell death by *apoptosis* (Kern et al, 2000).

The process of oxidation has been proposed as an adjunct to the mechanistic formation of AGEs from glucose and protein-glucose ketimines. Weiss et al (2000), describe how molecular oxygen in conjunction with metal catalysts, may bring about the formation of glyoxal and other intermediates prior to the crosslinking of proteins as AGEs. The mechanisms, in fact , remain somewhat speculative.

# **PART- II**

## AIM OF STUDY

- (1) To analyze the correlation between Diabetic retinopathy status and HbA1c values.
- (2) To study the relationship of HDL<sub>2</sub>/HDL<sub>3</sub> ratio with Diabetic Retinopathy status.

## METHOD OF STUDY

## MATERIALS AND METHODS

100 Diabetic patients between the age group of 30 to 60 years of either sex were included in this study. Both type 1 and type 2 diabetic patients were included . 20 normal cases were kept as control. 40 cases were diabetics without retinopathy ,and 60 patients were diabetics with retinopathy.

All the patients were subjected to detailed history and examination including detailed ocular examination, which included refraction ,intraocular pressure measurement, fundus examination, fundus fluorescein camera and angiography.

Scott's classification (years) was used for the grading of diabetic retinopathy.

Diabetes in all these patients was confirmed by estimating fasting and post-

prandial blood sugar. The blood samples from over night fasting patients were obtained in EDTA vials (1 mg/ ml of blood). Different fractions of lipoprotein were separated by using heparin manganese chloride and sodium dodecyl sulfate double precipitation technique. Total cholesterol and cholesterol content of lipoprotein fractions was estimated by the met by the method of Abell et al. Triglyceride was estimated by the technique of Van Handel and Zilversmit.

#### **SERUM CHOLESTEROL AND HDL SUBFRACTIONS ESTIMATION:**

It was done by Wybenga and Pileggi's method using strangen reagent kit. A simple and precise method for measuring HDL-cholesterol subfractions is by a single precipitation followed by homogenous HDL-cholesterol assay. HDL consists of two major subfractions, HDL2 and HDL3. This describes a simple method for assaying HDL subspecies by combining a single precipitation with a direct high density lipoprotein-cholesterol (HDL-C) assay. A precipitation reagent (0.06 ml) containing 1,071 U/ml heparin, 500 mmol/l MnCl<sub>2</sub> and 12 mg/ml dextran sulfate was added to a serum (0.3 ml). The sample was incubated and centrifuged at 10,000 rpm for 10 min. HDL3-C was measured by a homogenous HDL-C assay in the supernatant, and HDL2-C was estimated by subtracting the HDL3-C from the direct HDL-C. The HDL3-C and HDL2-C values determined by the precipitation method were identical to those

determined by ultracentrifugation, and there were excellent correlations between the methods in the measurements of HDL3-C and HDL2-C ( $r = 0.933$  and  $0.978$ , respectively;  $n = 102$ ). The two methods also proved to be highly correlated in the measurement of apolipoprotein A-I and A-II in HDL subfractions. The HDL-C subfractions determined by ultracentrifugation were more closely associated with the homogenous HDL-C assay than with the total cholesterol assay, especially in the hypertriglyceridemic samples.

**SERUM TRIGLYCERIDE ESTIMATION:** It is based on the following principle. N-heptane iso propanol mixture is used to separate out phospholipids from triglyceride, then triglycerides are hydrolysed by saponification with potassium hydroxide followed by acidification. Glycerol liberated by meta periodate to formaldehyde which is measured calorimetrically by reaction with acetyl acetone ammonia.

**ESTIMATION OF Hb1Ac :** By columnar method . The carbohydrate moiety of glycosylated haemoglobin is converted into hydroxyl methyl furfural by heating with phosphoric acid. The hydroxymethyl furfural is then incubated with Thiobarbituric acid to give a colored compound which is measured photometrically.

## **INSTRUMENTS USED**

1. Indirect and direct ophthalmoscope
2. Haag Streit Slit lamp
3. Goldmann's applanation tonometer
4. Goldmann's 3 mirror lens
5. Topcon fundus camera for fundus photography

## ANALYSIS AND DISCUSSION

In this analytical study, 100 patients of diabetes mellitus who attended the diabetes clinic in the department of diabetology in Government General Hospital, MMC, Chennai, from November 2006 to February 2007 were taken. The patients chosen were of the age group 30-60 years. Both type 1 and type 2 diabetic patients were included. 20 normal cases were kept as age matched control. Full detailed ophthalmic examination was carried out on all the patients. Blood analysis for lipid profile, which included HDL<sub>2</sub> and HDL<sub>3</sub> subfractions, Hb1Ac was also done meticulously using standard protocols for laboratory investigations.

### **Incidence and Prevalence**


Nearly 171 million people worldwide have diabetes. This figure is likely to double by 2030. India holds 31.7 million diabetic patients ranking first in the world. This number is projected to increase to 79.4 million by 2030.<sup>2</sup> In India, prevalence of DR has been reported to range from 10.5% to 26.2%. This study also reiterated the fact that the incidence of diabetic retinopathy is more in males compared to females. In this study the percentage of diabetic patients without retinopathy is 40 and those with retinopathy is 60. The further breakup of this 60 percent is NPDR 37% and PDR 23%.




**SEX INCIDENCE**

**1=MALE**

**2=FEMALE**






**CASES PROFILE**

**1=DM WITH RETINOPATHY**

**2=DM WITHOUT  
RETINOPATHY**

**3=CONTROLS**



## Prevalence

| Diabetes mellitus      | No. of cases | Percentage(%) |
|------------------------|--------------|---------------|
| DM without retinopathy | 40           | 40            |
| NPDR                   | 37           | 37            |
| PDR                    | 23           | 23            |

## Sex incidence

In this study , the percentage of males with diabetic retinopathy is 53.33 and females is 47. This finding correlated with the findings of earlier studies e.g. WEDSR, UKPDS, etc. that the incidence of diabetic retinopathy is more incident in males as compared to females.

| Sex    | No. of cases with diabetic retinopathy | Percentage(%) |
|--------|--|---------------|
| Male   | 32                                     | 53.33         |
| Female | 28                                     | 47            |

Out of 60 cases , 32 were male and 28 cases were female.

## CONTROL CASES TAKEN FOR STUDY

20 age matched control cases were taken for this study. 10 were males and 10 females.

## Analysis of Bio-chemical indices :


### HDL and HDL<sub>2</sub>/HDL<sub>3</sub> Subfractions ratio:

Study suggests that high HDL cholesterol may, independently of glycemic control, prevent the development of microvascular complications in diabetes. These results could be related to antioxidant, antithrombotic, and anti-inflammatory properties of HDL particles. Interestingly, structural modifications of HDL mediated by various mechanisms, including glycation, oxidation, and enzymatic degradation, may affect their functional and atheroprotective properties. This may suggest that not only quantity but also quality of HDL particles play a role in the damage of endothelium.


### HDL Values:

|                     | DM without retinopathy | NPDR  | PDR   |
|---------------------|------------------------|-------|-------|
| Mean                | 50.03                  | 47.14 | 46.43 |
| Standard deviation  | 7.9                    | 10.5  | 9.3   |
| P Value             | <0.05                  |       |       |
| Confidence interval | 1.68                   |       |       |

The above values show that HDL Values are abnormal both in DM without and with retinopathy patients. It is 50.03, 47.14 and 46.43 in DM without retinopathy, NPDR and PDR respectively. It also shows that lower values of HDL in patients with diabetic retinopathy shows a correlation with severity of diabetic retinopathy status. The 'p' value is <0.05 and confidence interval is 1.68, which shows that the data is statistically significant.



# HDL2/HDL3 RATIO




1= DM without retinopathy

2= DM with retinopathy

# HDL2:HDL3 ratio

## Frequency distribution





### HDL<sub>2</sub>/HDL<sub>3</sub> Subfractions ratio:

## HDL<sub>2</sub>/HDL<sub>3</sub> RATIO

|                     | DM without retinopathy | DM with retinopathy |
|---------------------|------------------------|---------------------|
| Mean                | 0.57                   | 0.52                |
| Standard Deviation  | 0.14                   | 0.18                |
| Confidence interval | 0.031                  |                     |
| 'p' value           | <0.05 Significant      |                     |

| DM without retinopathy | DM with retinopathy |  |
|------------------------|---------------------|--|
| 21                     | 5                   | HDL <sub>2</sub> /HDL <sub>3</sub> ratio N |
| 39                     | 35                  | HDL <sub>2</sub> /HDL <sub>3</sub> ratio ↓ |

ODD'S Ratio= 3.76

Chi square test: 6.4                      'P' value: <0.01


The mean HDL<sub>2</sub>/HDL<sub>3</sub> ratio in diabetics without retinopathy is 0.57 and in with retinopathy it is 0.52. This study shows a correlation with the decreased HDL<sub>2</sub>/HDL<sub>3</sub> ratio with the severity of diabetic retinopathy status. This is statistically highly significant , 'p' value being <0.05. Moreover the odds ratio of correlation of HDL<sub>2</sub>/HDL<sub>3</sub> ratio with developing retinopathy in diabetic patients is shown to be 3.76 , which is a significant finding. The above data was statistically analysed by chi square test which shows that the above findings are not chance findings, 'p' value being <0.01.

## HbA1c Values

|                     | DM without retinopathy | DM with retinopathy |
|---------------------|------------------------|---------------------|
| Mean                | 8.615                  | 8.313               |
| Standard Deviation  | 0.922524407            | 0.985396189         |
| Confidence interval | 0.18                   |                     |
| 'p' value           | <0.05 Significant      |                     |

Chi Square test: 4.1

According to the above data, the mean HbA1c values in patients of DM without retinopathy is 8.615% and in patients of DM with retinopathy is 8.313%. The confidence interval is 0.18. We assessed the HbA1c values in order to assess the control of diabetic status. The slightly lower values of HbA1c in patients of DM with retinopathy could be explained by the fact that there could be a tendency towards more strict glycemetic control in these subgroup of patients. As a corollary of the above findings , it can be postulated that the severity of diabetic retinopathy status bears a correlation with the level of glycosylated haemoglobin.



**TGL Values(mg/dl):**

|                     | DM without retinopathy | NPDR  | PDR   |
|---------------------|------------------------|-------|-------|
| Mean                | 76.77                  | 84.48 | 92.69 |
| Standard deviation  | 7                      | 36    | 55    |
| P Value             | <0.05                  |       |       |
| Confidence interval | 5.87                   |       |       |

The mean serum triglycerides ( $P < 0.05$ ) were higher in subjects with DR compared with those without DR. After adjusting for age, gender, duration of diabetes, total serum triglycerides were associated with DR. After adjusting for HbA<sub>1c</sub> and body mass index, triglycerides maintained a significant association with DR .

There is a significant association of serum triglycerides with DR. The p Value is <0.05 and the confidence interval is 5.87. This finding also correlates with the earlier study done I,e. the Chennai Urban Rural Epidemiology Study (CURES) Eye Study—2.

**TC Values(mg/dl):**

|                     | DM without retinopathy | NPDR   | PDR    |
|---------------------|------------------------|--------|--------|
| Mean                | 133.82                 | 148.77 | 151.33 |
| Standard deviation  | 13.76                  | 37.17  | 29.51  |
| P Value             | <0.05                  |        |        |
| Confidence interval | 4.50                   |        |        |

The mean serum total cholesterol concentrations were higher in subjects with DR compared with those without DR. It is 133.82, 148.77, 151.33 mg/dl in DM without retinopathy, NPDR and PDR respectively. The above finding is statistically significant because p value is <0.05 and the confidence interval is 4.50.

### **LDL Values (mg/dl):**


|                     | DM without retinopathy | NPDR  | PDR   |
|---------------------|------------------------|-------|-------|
| Mean                | 68.43                  | 83.82 | 84.66 |
| Standard deviation  | 13.80                  | 28.17 | 25.08 |
| P Value             | <0.05                  |       |       |
| Confidence interval | 4.38                   |       |       |

The above data clearly shows that there is a clear correlation between the level of LDL values and the severity of Diabetic retinopathy. The mean LDL values are 68.43 ,83.82 , 84.66 mg/dl in patients of DM without retinopathy, NPDR and PDR respectively. The above finding is statistically significant because p value is <0.05 and the confidence interval is 4.38.

This study revealed the following relevant observations, which could be regarded as novel findings:


1. Significantly lower values of HDL in patients with diabetic retinopathy shows a correlation with severity of diabetic retinopathy status .

# TGL Values




1= DM without retinopathy  
2= NPDR  
3= PDR

# TC



1=DM without retinopathy  
2= NPDR  
3= PDR





2. Study suggests that high HDL cholesterol may, independently of glycemic control, prevent the development of microvascular complications in diabetes.
3. This study shows a correlation with the decreased HDL<sub>2</sub>/HDL<sub>3</sub> ratio with the severity of diabetic retinopathy status.
4. This may suggest that not only quantity but also quality of HDL particles play a role in the damage of endothelium.

## SUMMARY

1. In this study 100 patients of diabetes mellitus who attended the diabetes clinic in the department of diabetology in Government General Hospital , MMC, Chennai , from November 2006 to February 2007 were taken.
2. 40 cases were diabetics without retinopathy ,and 60 patients were diabetics with retinopathy.
3. 20 normal cases were kept as age matched control.

### 4. AGE GROUP

The patients chosen were of the age group 30-60 years.

### 5. SEX INCIDENCE

In this study , the percentage of males with diabetic retinopathy is 53.33 and females is 47. Males are affected more than the females.

### 6. CLINICAL PROFILE

40 cases were diabetics without retinopathy ,and 60 patients were diabetics with retinopathy. Of these 60 cases , 37 were of NPDR and 23 were of PDR, i.e. 37% and 23% respectively.

20 cases were taken from normal age matched population and were kept as controls.

### BIO-CHEMICAL INDICES STUDIED

### 7. HDL

**HDL** values are abnormal both in DM without and with retinopathy patients. It is 50.03 , 47.14 and 46.43 in DM without retinopathy, NPDR and PDR respectively.

It also shows that lower values of HDL in patients with diabetic retinopathy shows a correlation with severity of diabetic retinopathy status .

#### 8. **HDL<sub>2</sub>/HDL<sub>3</sub> Subfractions ratio**

The mean HDL<sub>2</sub>/HDL<sub>3</sub> ratio in diabetics without retinopathy is 0.57 and in with retinopathy it is 0.52. This study shows a correlation with the decreased HDL<sub>2</sub>/HDL<sub>3</sub> ratio with the severity of diabetic retinopathy status. The odds ratio of correlation of HDL<sub>2</sub>/HDL<sub>3</sub> ratio with developing retinopathy in diabetic patients is shown to be 3.76

Data was statistically analyzed by chi square test which shows that the above findings are not chance findings, 'p' value being <0.01.

#### 9. **HbA1c Values**

The mean HbA1c values in patients of DM without retinopathy is 8.615% and in patients of DM with retinopathy is 8.313%. The confidence interval is 0.18. The slightly lower values of HbA1c in patients of DM with retinopathy could be explained by the fact that there could be a tendency towards more strict glycemic control in these subgroup of patients.

## 10. TGL Values

The mean serum triglycerides ( $P < 0.05$ ) were higher in subjects with DR compared with those without DR. It is 76.77, 84.48 and 92.69 mg/dl in cases of DM without retinopathy, NPDR and PDR respectively. After adjusting for age, gender, duration of diabetes, total serum triglycerides were associated with DR. After adjusting for HbA<sub>1c</sub> and body mass index, triglycerides maintained a significant association with DR.

## 11. TC Values

The mean serum total cholesterol concentrations were higher in subjects with DR compared with those without DR. It is 133.82, 148.77, 151.33 mg/dl in DM without retinopathy, NPDR and PDR respectively. There is a direct relation between the mean serum total cholesterol concentrations and the severity of diabetic retinopathy. It is statistically significant because p value is  $<0.05$ .

## 12. LDL Values

There is a clear correlation between the level of LDL values and the severity of Diabetic retinopathy. The mean LDL values are 68.43, 83.82, 84.66 mg/dl in patients of DM without retinopathy, NPDR and PDR respectively. It is statistically significant because p value is  $<0.05$ . We can see that the severity of Diabetic retinopathy status is in direct

proportion with the level of LDL values in the different subcategories of diabetic retinopathy patients.

To summarize ,our study suggests that high HDL cholesterol may, independently of glycemic control, prevent the development of microvascular complications in diabetes. These results could be related to antioxidant, antithrombotic, and anti-inflammatory properties of HDL particles . Interestingly, structural modifications of HDL mediated by various mechanisms, including glycation, oxidation, and enzymatic degradation, may affect their functional and atheroprotective properties . This may suggest that not only quantity but also quality of HDL particles play a role in the damage of endothelium.

We assessed the HbA1c values in order to assess the control of diabetic status. As a corollary of the above findings , it can be postulated that the severity of diabetic retinopathy status bears a correlation with the level of glycosylated haemoglobin.

## CONCLUSIONS

From this study we were able to arrive at the following conclusions.

1. Males are affected more than the females i.e. the incidence of diabetic retinopathy is more incident in males as compared to females.
2. In India, prevalence of DR has been reported to range from 10.5% to 26.2%
3. In the clinical profile of the patients , NPDR was more prevalent than PDR.
4. This study shows a correlation with the decreased HDL<sub>2</sub>/HDL<sub>3</sub> ratio with the severity of diabetic retinopathy status. The odds ratio of correlation of HDL<sub>2</sub>/HDL<sub>3</sub> ratio with developing retinopathy in diabetic patients is shown to be 3.76
5. We assessed the HbA1c values in order to assess the control of diabetic status. As a corollary of the above findings , it can be postulated that the severity of diabetic retinopathy status bears a correlation with the level of glycosylated haemoglobin.

6. After adjusting for age, gender, duration of diabetes, total serum triglycerides were associated with DR in direct proportional relation. After adjusting for HbA<sub>1c</sub> and body mass index, triglycerides maintained a significant direct association with DR .
7. There is a direct relation between the mean serum total cholesterol concentrations and the severity of diabetic retinopathy.
8. The severity of Diabetic retinopathy status is in direct proportion with the level of LDL values in the different subcategories of diabetic retinopathy patients.
9. Structural modifications of HDL mediated by various mechanisms, including glycation, oxidation, and enzymatic degradation, may affect their functional and atheroprotective properties. This may suggest that not only quantity but also quality of HDL particles play a role in the damage of endothelium.

# **PART- III**



## BIBLIOGRAPHY

### TEXT BOOK REFERENCES

1. Anthony S Fauci, Eugene Braunwald, Kurt J Isselbacher. Harrison's Principles of Internal Medicine. 14<sup>th</sup> edition, volume 2. McGraw-Hill publishers. 1998: 2061-2078.
2. "Diabetes Action now: An Initiative of the World Health Organization & the, International Diabetes Federation" A WHO publication, 2004 pg: 10.
3. Albert & Jakobiec. Principles and Practice of Ophthalmology. 2<sup>nd</sup> edition, volume 3. W.B. Saunders company, 2000: 1900-1913.
4. "Blindness: vision 2020- control of major blinding disease & disorders", A WHO publication, Feb 2000.
5. Agarwal S, Raman R, Paul PG, Rani PK, Uthra S, Gayathree, McCarty C, Kumaramanickavel G, Sharma T. Sankara Nethralaya-Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS 1): study design and research methodology, Ophthalmic Epidemiol. 2005 Apr; 12(2): 143-53.

6. Nirmalan PK, Katz J, Robin AL, Tielsch JM, Namperumalsamy, Kim R, Narendran V, Ramakrishnan R, Krishnadas R, Thulasiraj D, Suan E. Prevalence of vitreoretinal disorders in a rural population of southern India: the Aravind Comprehensive Eye Study. *Arch Ophthalmol.* 2004 Apr; 122(4):581-6
7. Survey of visual impairment in an Indian tertiary eye hospital, Herse P, Gothwal VK, *Indian J Ophthalmol.* 1997 Sep;45(3):189-93
8. Narendran, R K John, A Raghuram, R D Ravindran, P K Nirmalan, and R D Thulasiraj. Diabetic retinopathy among self reported diabetics in southern India: a population based assessment. *Br. J. Ophthalmol.*, Sep 2002; 86: 1014 - 1018.
9. Donald S. Fong, Lloyd Aiello, Thomas W. Gardner, et al. Diabetic retinopathy – Position statement. *Diabetic care*; 26: 226-229, Jan 2003.
10. Rema M, Ponnaiya M, Mohan V. Prevalence of retinopathy in non insulin dependent diabetes mellitus at a diabetes centre in southern India. *Diabetes Res Clin Pract.* 1996 Sep;34(1):29-36.
11. Pierro L, Brancato R, Robino X, et al. Axial length in patients with diabetes. *Retina.* 1999;19(5):401-4
12. Liverpool Diabetic Eye Study: Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Younis N, Broadbent DM, Vora JP, Harding SP; *Lancet.* 2003 Jan 18;361(9353):195-200

13. Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V.  
Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural  
Epidemiology Study (CURES) eye study, I. *Invest Ophthalmol Vis Sci.* 2005  
Jul;46(7):2328-33
14. Sharma R.A Diabetic eye disease in southern India. *Community Eye health*  
1996;9: 56-58.
15. Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs  
– An Extension of the Modified Airlie House Classification. Early treatment  
diabetic retinopathy study research group. *Ophthalmology* 1991; 98:786-806
16. United kingdom prospective study, 30 Diabetic Retinopathy at Diagnosis of  
Non-Insulin-Dependent Diabetes Mellitus and Associated Risk Factors Eva  
M.Kohner, MD; Stephen J.Aldington, DMS; Irene M.Stratton, MSc; Susan  
E.Manley, PhD; Rury R.Holman, MD; David R.Mathews, MD; Robert  
C.Turner, MD; for the United Kingdom Prospective Diabetes Study *Arch*  
*Ophthalmol.* 1998;116:297-303
17. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-  
year incidence and progression of diabetic retinopathy and associated risk  
factors in type 1 diabetes. Klein R, Klein BE, Moss SE, Cruickshanks KJ.  
*Ophthalmology.* 1998 Oct;105(10):1801-15
18. Dandona L, Dandona R, Naduvilath TJ, et al. Refractive errors in an urban  
population in Southern India: the Andhra Pradesh Eye Disease Study. *Invest*  
*Ophthalmol Vis Sci.* 1999;40:2810–2818.

19. Fledelius HC. Is myopia getting more frequent? A cross-sectional study of 1416 Danes aged 16 years+. *Acta Ophthalmol (Copenh)* 1983;61:545–59.
20. Jain IS, Luthra CL, Das T. Diabetic retinopathy and its relation to errors of refraction. *Arch Ophthalmol* 1967;77:59–60.
21. Rand LI, Krolewski AS, Aiello LM, Warram JH, Baker RS, Maki T. Multiple factors in the prediction of risk of proliferative diabetic retinopathy. *N Engl J Med* 1985;313:1433–8.
22. Horner JF Quoted by Duke Elder S. *System of Ophthalmology* London: Kimpton 1970:5
23. Granstrom KO. Refraktionsveränderungen bei diabetes mellitus. *Acta Ophthalmol(Kbh)*1933;11:1-161
24. Duke Elder S Changes in refraction in diabetes mellitus. *British journal of ophthalmology* 1925;9:167-87
25. Roberts W Rapid lens changes in diabetes mellitus. *Am journal of ophthalmology* 1951;33:1283-5
26. Refractive change in diabetic patients during intensive glycaemic control  
Fumiki Okamoto, Hirohito Sone, Tomohito Nonoyama, Sachiko Hommura.  
*Br. J. Ophthalmology* 2000; 84:1097-1102
27. Planten J . Physiological optic approach of lens and cataract.  
*Ophthalmologica* 1975;171:199-206
28. Feinblum SM Clinical significance of refractive change in diabetes.  
*Optometric weekly* 1972;63:199-206

29. Refractive change in hyperglycaemia: hyperopia or myopia; Paul Riordan  
Eva, Patrica T, Pascoe and Daniel G Vaughan; *British journal of  
Ophthalmology* 1982 ,66, 500-505
30. American Academy of ophthalmology (sec11- lens and cataract) pg. 60
31. Paediatric ophthalmology and strabismus: David Taylor and Creig Hoyt: pg  
43 & 54
32. Larsen JS The sagittal growth of eye I-IV. *Acta Ophthalmol*(Copenhagen)  
1971;49:239-62,427-40, 441-53,873-86
33. The absence of diabetic retinopathy in patients with retinitis pigmentosa:  
implications for pathophysiology and possible treatment: G B Arden; *Br J  
Ophthalmol* 366 2001;85:366–370
34. The negative coincidence of retinitis pigmentosa and proliferative diabetic  
retinopathy. Sternberg P Jr, Landers MB 3rd, Wolbarsht M. *Am J  
Ophthalmol.* 1984 Jun;97(6):788-9.
35. Modifying factors related to asymmetric diabetic retinopathy. Dogru M,  
Inoue M, Nakamura M, Yamamoto M. *Eye.* 1998;12 ( Pt 6):929-33.
36. Occurrence of changes in the eye in diabetic retinopathy with significant  
myopia Dujčić M, Misailović K, Nikolić Lj, Ignjacev M. *Srp Arh Celok Lek.*  
1998 Nov-Dec;126(11-12):457-60.
37. Ocular factors in the incidence and progression of diabetic retinopathy. Moss  
SE, Klein R, Klein BE. *Ophthalmology.* 1994 Jan;101(1):77-83.

38. Influence of HLA-DR phenotype and myopia on the risk of nonproliferative and proliferative diabetic retinopathy; Baker RS, Rand LI, Krolewski AS, et al.: *Am J Ophthalmol* 1986, 102:693–700.
39. A new pressure attenuation index to evaluate retinal circulation. A link to protective factors in diabetic retinopathy; Quigley M, Cohen S.: *Arch Ophthalmol* 1999, 117:84–89.
40. Chennai Urban Rural Epidemiology Study (CURES) Eye Study—2

## PROFORMA

NAME:

AGE:

SEX: F/M

OP/IP NO.

OCCUPATION:

AGE:

PERSONAL HISTORY: SMOKING/ALCOHOLIC

VEGETARIAN/NON-VEGETARIAN

AGE OF ONSET OF DIABETES:

ANY OTHER DISORDER:

DURATION OF DIABETES:

CONTROL OF DIABETES: MEDICATIONS

COMPLAINTS:

OCULAR EXAMINATION: RE/LE

VISUAL ACUITY

LIDS

CONJ

CORNEA

ANTERIOR CHAMBER

PUPIL

IRIS

LENS

TENSION

RETINOSCOPY

SUBJECTIVE

VISION CORRECTION

FUNDUS

A. DISTANT DIRECT

B. DIRECT

MEDIA/DISC/VESSELS

SLIT LAMP EXAMINATION

SYSTEMIC EXAMINATION

INVESTIGATION

BLOOD PRESSURE

URINE:

ALBUMIN/SUGAR/DEPOSITS



TC/DC/ESR/HB

FASTING BLOOD SUGAR

GLYCOSYLATED HAEMOGLOBIN

SERUM TRIGLYCERIDES

SERUM CHOLESTEROL

HDL

HDL<sub>2</sub>

HDL<sub>3</sub>

FFA: LEAKAGE

AREAS OF CAPILLARY NON PERFUSION

NEOVASCULARISATION

IRMA

DIAGNOSIS:

| NAME         | AGE | SEX | DURATION | DIAGNOSIS | FBS(mg%) | HbA1c(%) | TGL(mg/dl) | TC(mg/dl) | HDL(mg/dl) | LDL(mg/dl) | HDL3(mg/c) | HDL2(mg/c) | HDL2:HDL3 ratio |
|--------------|-----|-----|----------|-----------|----------|----------|------------|-----------|------------|------------|------------|------------|-----------------|
| Munusamy     | 32  | M   | 5        | DM        | 260      | 8.3      | 62         | 128       | 53.6       | 62         | 29.9       | 23.7       | 0.79            |
| Veeran       | 31  | M   | 6        | DM        | 180.5    | 7.6      | 66.2       | 140       | 56.6       | 70.16      | 39.5       | 17.1       | 0.43            |
| Subramani    | 40  | M   | 4        | DM        | 110      | 9.3      | 66         | 116       | 54.4       | 48.4       | 29.7       | 24.7       | 0.83            |
| Joseph       | 32  | M   | 3        | DM        | 88.2     | 10.3     | 72.4       | 128       | 59.4       | 54.12      | 38.8       | 20.6       | 0.53            |
| Balakondaiya | 54  | M   | 4        | DM        | 112      | 7.6      | 68         | 122.6     | 48.5       | 60.5       | 29.6       | 18.9       | 0.64            |
| Elumalai     | 44  | M   | 5        | DM        | 118      | 8        | 72         | 123.6     | 51.2       | 58         | 32.9       | 18.3       | 0.56            |
| Chinnaya     | 43  | M   | 4        | DM        | 103      | 8.5      | 81.6       | 126       | 54.4       | 55.28      | 38.7       | 15.7       | 0.41            |
| Yusuf        | 54  | M   | 5        | DM        | 72.8     | 10.2     | 81.6       | 140.1     | 51.4       | 72.38      | 34.2       | 17.2       | 0.5             |
| Govindan     | 43  | M   | 3        | DM        | 166      | 9.5      | 84.8       | 144.6     | 43.2       | 84.44      | 29.5       | 13.7       | 0.46            |
| Rajan        | 33  | M   | 5        | DM        | 133      | 7.9      | 81         | 141       | 53.2       | 71.6       | 38.12      | 15.1       | 0.4             |
| Govindasamy  | 56  | M   | 7        | DM        | 129      | 8.9      | 68.8       | 128       | 48.6       | 65.64      | 29.7       | 18.9       | 0.64            |
| Venkatesan   | 44  | M   | 5        | DM        | 246      | 8.9      | 77.4       | 148       | 48.7       | 83.82      | 32.7       | 16         | 0.49            |
| Moorthy      | 54  | M   | 6        | DM        | 95       | 8.5      | 77.2       | 106       | 42.6       | 47.96      | 26.2       | 16.4       | 0.63            |
| Thirumal     | 34  | M   | 5        | DM        | 161      | 6.9      | 71.7       | 121       | 48.9       | 57.76      | 32.7       | 16.2       | 0.5             |
| Pichai       | 37  | M   | 4        | DM        | 309      | 8.1      | 83.2       | 129       | 45.6       | 66.76      | 31.4       | 14.2       | 0.45            |
| Shiva        | 51  | M   | 3        | DM        | 127.8    | 8.9      | 67.4       | 138       | 51.8       | 72.72      | 34.2       | 17.6       | 0.51            |
| Isac         | 54  | M   | 5        | DM        | 112.8    | 8.5      | 78.5       | 146       | 52.9       | 77.4       | 32.8       | 20.1       | 0.61            |
| Perumal      | 56  | M   | 3        | DM        | 75       | 6.9      | 77.4       | 152       | 54.4       | 82.12      | 29.4       | 25         | 0.85            |
| Rudran       | 43  | M   | 6        | DM        | 102      | 8.1      | 79.2       | 141       | 53.8       | 71.36      | 33.6       | 20.2       | 0.6             |
| Selvam       | 32  | M   | 3        | DM        | 92       | 9.4      | 74.3       | 121.6     | 48.9       | 57.84      | 27.6       | 21.3       | 0.77            |
| Kumar        | 47  | M   | 5        | DM        | 184.5    | 9.9      | 86         | 127.4     | 48.4       | 61.8       | 28.4       | 20         | 0.7             |
| Velu         | 49  | M   | 3        | DM        | 223      | 11.2     | 74.4       | 108.7     | 52.8       | 41.02      | 32.1       | 20.7       | 0.64            |
| Thirumoorthy | 35  | M   | 7        | DM        | 173      | 7.8      | 68.4       | 126.4     | 48.9       | 63.82      | 30.4       | 18.5       | 0.61            |
| Thirumalai   | 46  | M   | 8        | DM        | 182      | 7.7      | 77.4       | 141       | 53.6       | 71.92      | 28.9       | 24.7       | 0.85            |
| Venkatasamy  | 56  | M   | 8        | DM        | 105      | 7.6      | 71.3       | 134.7     | 51.7       | 68.74      | 30.4       | 21.3       | 0.7             |
| Raju         | 45  | M   | 8        | DM        | 164.4    | 9.3      | 84.4       | 142       | 46.3       | 78.82      | 28.6       | 17.7       | 0.62            |
| Baskaran     | 34  | M   | 8        | DM        | 103      | 7.6      | 88.6       | 146       | 45.6       | 82.68      | 30.41      | 15.2       | 0.5             |
| Chintamani   | 45  | M   | 6        | DM        | 166      | 9.5      | 66.2       | 128       | 52.2       | 62.56      | 39.4       | 12.8       | 0.32            |
| Yellamalai   | 34  | M   | 4        | DM        | 121      | 8.2      | 68.8       | 112       | 46.8       | 51.44      | 28.5       | 18.3       | 0.64            |
| Chinnatha    | 45  | F   | 6        | DM        | 211      | 8.3      | 95.6       | 124.4     | 50.6       | 54.68      | 35.9       | 14.7       | 0.41            |
| Saroja       | 35  | F   | 7        | DM        | 131      | 8.4      | 84.4       | 126.8     | 52.4       | 57.52      | 32.6       | 19.8       | 0.61            |
| Annatha      | 39  | F   | 5        | DM        | 94       | 8.3      | 72.5       | 146       | 54.4       | 77.1       | 30.1       | 24.3       | 0.81            |
| Panchali     | 40  | F   | 4        | DM        | 133      | 8.4      | 88.6       | 160       | 42.6       | 99.68      | 28.5       | 14.1       | 0.49            |
| Govindamma   | 57  | F   | 7        | DM        | 211      | 8.4      | 72.2       | 128.8     | 46.6       | 67.76      | 31.8       | 14.8       | 0.47            |
| Dilli Bai    | 58  | F   | 5        | DM        | 131      | 8.3      | 76.2       | 142       | 49.2       | 77.56      | 29.7       | 19.5       | 0.66            |
| Noorbibi     | 57  | F   | 7        | DM        | 94       | 8.6      | 86         | 148       | 48.5       | 82.3       | 27.8       | 20.7       | 0.74            |
| Kamala       | 38  | F   | 2        | DM        | 133      | 8.3      | 80.9       | 157.3     | 46.7       | 94.42      | 30.1       | 16.6       | 0.55            |
| Anandi       | 55  | F   | 3        | DM        | 211      | 9.4      | 88.6       | 147.3     | 42.6       | 86.98      | 32.6       | 10         | 0.31            |
| Seetha       | 56  | F   | 5        | DM        | 154      | 9.6      | 76.7       | 109.7     | 46.7       | 47.66      | 33.1       | 13.6       | 0.41            |
| Kanthammal   | 57  | F   | 2        | DM        | 74       | 9.5      | 73         | 156       | 52.6       | 88.8       | 34.8       | 17.8       | 0.51            |
| Kamban       | 54  | M   | 10       | NFDR      | 156      | 7.7      | 120        | 168       | 53.6       | 90.4       | 36.9       | 16.7       | 0.45            |
| Vellai       | 53  | M   | 11       | NFDR      | 160      | 8.4      | 91         | 159       | 46.6       | 94.2       | 28.6       | 18         | 0.63            |
| Krishnasamy  | 56  | M   | 11       | NFDR      | 144      | 8.2      | 98         | 138       | 46.1       | 72.3       | 28.5       | 17.6       | 0.62            |
| Rajendran    | 56  | M   | 13       | NFDR      | 130      | 8.3      | 138        | 151       | 45         | 79         | 31.6       | 13.4       | 0.42            |
| Muhamed      | 51  | M   | 12       | NFDR      | 160      | 8.7      | 40         | 115       | 41         | 66         | 33.2       | 7.8        | 0.23            |
| Babu         | 56  | M   | 12       | NFDR      | 144      | 8.5      | 50         | 114       | 42.6       | 59.2       | 26.7       | 15.9       | 0.6             |
| Suresh       | 58  | M   | 9        | NFDR      | 162      | 8.3      | 80         | 147       | 53.6       | 77.4       | 32.4       | 21.2       | 0.65            |
| Yesu         | 59  | M   | 8        | NFDR      | 154      | 8.2      | 141        | 110       | 30.7       | 51.1       | 20.4       | 10.3       | 0.5             |
| Durairaj     | 54  | M   | 12       | NFDR      | 115      | 8.4      | 49         | 100       | 37.7       | 52.5       | 21.5       | 16.2       | 0.75            |
| Basha        | 53  | M   | 13       | NFDR      | 123      | 8.3      | 44         | 126.4     | 32.1       | 85.5       | 20.4       | 11.7       | 0.57            |
| Palani       | 56  | M   | 12       | NFDR      | 209      | 8.3      | 45         | 106       | 49.6       | 48         | 29.6       | 20         | 0.68            |
| Swaminathan  | 57  | M   | 11       | NFDR      | 262      | 8.2      | 79         | 132       | 43.1       | 73.1       | 28         | 15.1       | 0.54            |
| Muniyandi    | 56  | M   | 11       | NFDR      | 179      | 8.3      | 48         | 87        | 30.7       | 46.7       | 21         | 6.7        | 0.32            |
| Nagaraj      | 55  | M   | 10       | NFDR      | 180      | 8.1      | 96         | 133       | 43.5       | 70.7       | 28.3       | 15.2       | 0.54            |
| Andiappan    | 55  | M   | 9        | NFDR      | 150      | 8.6      | 98         | 138       | 36.1       | 72.4       | 24.9       | 11.2       | 0.45            |
| Chuppan      | 50  | M   | 12       | NFDR      | 170      | 8.2      | 72         | 134.6     | 54.3       | 65.9       | 33.7       | 20.6       | 0.61            |
| Vishnu       | 49  | M   | 13       | NFDR      | 132      | 8.6      | 177        | 239       | 37.8       | 165.8      | 27.6       | 10.2       | 0.37            |
| Chittan      | 48  | M   | 12       | NFDR      | 159      | 8.2      | 82         | 136       | 44.3       | 75.3       | 28.3       | 16         | 0.57            |
| Ganesan      | 47  | M   | 12       | NFDR      | 102      | 8.3      | 111        | 203       | 46.3       | 134.5      | 24.7       | 21.6       | 0.87            |
| Velan        | 48  | M   | 13       | NFDR      | 146      | 8.6      | 65         | 108       | 38.1       | 56.9       | 21.8       | 16.3       | 0.75            |
| Rama         | 49  | F   | 12       | NFDR      | 143      | 8.3      | 54         | 179       | 64         | 105        | 40.3       | 24         | 0.6             |
| Susheela     | 55  | F   | 11       | NFDR      | 123      | 8.5      | 148        | 208       | 66.7       | 111.7      | 42.6       | 24.1       | 0.57            |
| Karpagam     | 60  | F   | 11       | NFDR      | 112      | 8.3      | 68         | 164       | 70         | 80.4       | 46.7       | 23.3       | 0.5             |
| Nalini       | 47  | F   | 13       | NFDR      | 76       | 10.9     | 147        | 246       | 55.3       | 161        | 34.1       | 21.2       | 0.62            |
| Sheela       | 54  | F   | 12       | NFDR      | 92       | 9.4      | 98         | 143       | 35.5       | 88         | 21.4       | 14.1       | 0.66            |
| Muniammal    | 56  | F   | 11       | NFDR      | 184      | 6.2      | 46         | 116       | 47.5       | 59.3       | 28.9       | 18.6       | 0.64            |
| Rukmani      | 58  | F   | 11       | NFDR      | 223      | 7.6      | 76         | 145       | 41.5       | 88.3       | 24.3       | 17.2       | 0.71            |
| Govindamma   | 48  | F   | 11       | NFDR      | 154      | 7.4      | 65.5       | 120.3     | 44.5       | 62.7       | 30.5       | 14         | 0.46            |
| Selvi        | 58  | F   | 11       | NFDR      | 105      | 8.6      | 130        | 152       | 31.6       | 94.4       | 20         | 11.6       | 0.58            |
| Nagammal     | 54  | F   | 10       | NFDR      | 106      | 8.2      | 42         | 180       | 67.1       | 104.5      | 38.7       | 28.4       | 0.73            |
| Lalitha      | 54  | F   | 11       | NFDR      | 115      | 8.6      | 134.7      | 147       | 48.4       | 71.6       | 32.4       | 16         | 0.49            |
| Sarada       | 56  | F   | 12       | NFDR      | 143      | 9.4      | 67         | 134       | 48.7       | 71.9       | 32.6       | 16.1       | 0.49            |
| Kamakshi     | 54  | F   | 12       | NFDR      | 157      | 9.9      | 55.2       | 206       | 51.9       | 143        | 38.7       | 13.2       | 0.34            |
| Sowmya       | 55  | F   | 13       | NFDR      | 167      | 7.4      | 44         | 120       | 49.7       | 61.5       | 29.8       | 19.9       | 0.67            |
| Gowri        | 57  | F   | 12       | NFDR      | 134      | 7.6      | 62         | 160       | 53.2       | 94.4       | 30.4       | 22.8       | 0.75            |
| Neela        | 53  | F   | 11       | NFDR      | 145      | 8.9      | 47         | 126       | 40.5       | 76.4       | 30.4       | 10.1       | 0.33            |
| Rasathi      | 53  | F   | 12       | NFDR      | 165      | 10.8     | 120        | 168       | 52.5       | 91.5       | 40.8       | 11.7       | 0.29            |
| Meenu        | 52  | F   | 11       | NFDR      | 167      | 7.1      | 82         | 194       | 70         | 83         | 36.7       | 33.3       | 0.91            |
| Nithyanand   | 56  | M   | 14       | PDR       | 180      | 8.6      | 68         | 130       | 49.3       | 67.1       | 30.2       | 19.1       | 0.63            |
| Mari         | 58  | M   | 15       | PDR       | 154      | 7.6      | 88         | 195       | 68.5       | 108        | 33.4       | 35.1       | 1.05            |
| Nagaiyah     | 59  | M   | 16       | PDR       | 134      | 7.5      | 63         | 134       | 49.7       | 71.6       | 32.4       | 17.3       | 0.53            |
| Mehamood     | 59  | M   | 16       | PDR       | 102      | 8.1      | 78         | 148       | 45.8       | 79.6       | 34.5       | 11.3       | 0.33            |
| Gopal        | 58  | M   | 17       | PDR       | 104      | 8.4      | 148        | 167       | 58.3       | 79.1       | 31.8       | 26.5       | 0.83            |
| Pichandi     | 57  | M   | 18       | PDR       | 166      | 6.9      | 64         | 140       | 51.4       | 75.8       | 34.7       | 16.7       | 0.48            |
| Sethu        | 58  | M   | 18       | PDR       | 122      | 8.3      | 52         | 117       | 43.2       | 63.4       | 26.2       | 17         | 0.65            |
| Kumar        | 60  | M   | 16       | PDR       | 211      | 8.7      | 49         | 114       | 42         | 62.2       | 26         | 16         | 0.62            |
| Ganesan      | 58  | M   | 17       | PDR       | 131      | 9.4      | 284        | 149       | 45         | 49         | 27.9       | 17.1       | 0.61            |
| Seethammal   | 56  | M   | 15       | PDR       | 94       | 8        | 88.8       | 214.4     | 41.6       | 154.6      | 28.9       | 12.7       | 0.44            |
| Perumal      | 55  | M   | 19       | PDR       | 133      | 7.6      | 184.5      | 168.5     | 34.4       | 67.2       | 24.3       | 10.1       | 0.42            |
| Andiappan    | 55  | M   | 18       | PDR       | 211      | 7.3      | 118        | 153       | 35.3       | 94         | 24.8       | 10.5       | 0.42            |
| Ranga        | 58  | M   | 18       | PDR       | 154      | 7.1      | 128        | 208       | 42.3       | 140        | 36.9       | 5.4        | 0.15            |
| Padmanaban   | 59  | M   | 18       | PDR       | 74       | 11.7     | 46         | 138       | 44.7       | 84         | 34.3       | 10.4       | 0.3             |
| Dhanam       | 59  | F   | 19       | PDR       | 156      | 7.1      | 55         | 122       | 41.5       | 69.5       | 31.9       | 9.6        | 0.3             |
| Ahalya       | 58  | F   | 19       | PDR       | 160      | 10.6     | 86         | 201       | 63.2       | 120.6      | 48.6       | 14.6       | 0.3             |
| Nandini      | 57  | F   | 17       | PDR       | 115      | 7.4      | 63         | 143       | 46.9       | 83.5       | 38.6       | 8.3        | 0.22            |
| Sheela       | 57  | F   | 17       | PDR       | 114      | 8.2      | 53         | 129       | 46.2       | 72.2       | 32.7       | 13.5       | 0.41            |
| Seethammal   | 56  | F   | 19       | PDR       | 134      | 8.6      | 45         | 131       | 43.6       | 78.4       | 33.8       | 9.8        | 0.29            |
| Kamalammal   | 56  | F   | 20       | PDR       | 179      | 7.2      | 77         | 141       | 40.8       | 84.8       | 31.7       | 9.1        | 0.29            |
| Rajathi      | 59  | F   | 16       | PDR       | 82       | 7.4      | 114        | 158       | 43.5       | 91.7       | 30.5       | 13         | 0.43            |
| Kasthuri     | 56  | F   | 15       | PDR       | 178      | 7.6      | 87         | 128       | 44.3       | 66.3       | 35.4       | 8.9        | 0.25            |
| Ekambaram    | 44  | M   | NA       | N         | 75       | 4.3      | 62         | 128       | 53.6       | 62         | 29.9       | 23.7       | 0.79            |
| Venkatesh    | 55  | M   | NA       | N         | 68.3     | 4.5      | 66.2       | 140       | 56.6       | 70.16      | 39.5       | 17.1       | 0.43            |
| Velmurugan   | 34  | M   | NA       | N         | 84.4     | 4.5      | 66         | 116       | 54.4       | 48.4       | 29.7       | 24.7       | 0.83            |
| Thangavel    | 45  | M   | NA       | N         | 66.4     | 4.5      | 72.4       | 128       | 59.4       | 54.12      | 38.8       | 20.6       | 0.53            |
| Thirumalai   | 23  | M   | NA       | N         | 72       | 4.6      | 68         | 122.6     | 48.5       | 60.5       | 29.6       | 18.9       | 0.64            |
| Natesan      | 54  | M   | NA       | N         | 69       | 4.6      | 72         | 123.6     | 51.2       | 58         | 32.9       | 18.3       | 0.56            |
| Gyanavel     | 45  | M   | NA       | N         | 71       | 4.7      | 81.6       | 126       | 54.4       | 55.28      | 38.7       | 15.7       |                 |

|             |      |    |        |      |     |      |       |
|-------------|------|----|--------|------|-----|------|-------|
| Sheela      | 57 F |    | 17 PDR | 114  | 8.2 | 53   | 129   |
| Seethammal  | 56 F |    | 19 PDR | 134  | 8.6 | 45   | 131   |
| Kamalammal  | 56 F |    | 20 PDR | 179  | 7.2 | 77   | 141   |
| Rajathi     | 59 F |    | 16 PDR | 82   | 7.4 | 114  | 158   |
| Kasthuri    | 56 F |    | 15 PDR | 178  | 7.6 | 87   | 128   |
| Ekambaram   | 44 M | NA | N      | 75   | 4.3 | 62   | 128   |
| Venkatesh   | 55 M | NA | N      | 68.3 | 4.5 | 66.2 | 140   |
| Velmurugan  | 34 M | NA | N      | 84.4 | 4.5 | 66   | 116   |
| Thangavel   | 45 M | NA | N      | 66.4 | 4.5 | 72.4 | 128   |
| Thirumalai  | 23 M | NA | N      | 72   | 4.6 | 68   | 122.6 |
| Natesan     | 54 M | NA | N      | 69   | 4.6 | 72   | 123.6 |
| Gyanavel    | 45 M | NA | N      | 71   | 4.7 | 81.6 | 126   |
| Venkatasan  | 34 M | NA | N      | 72.4 | 4.7 | 81.6 | 140.1 |
| Dakshinamoc | 55 M | NA | N      | 80.9 | 4.6 | 84.8 | 144.6 |
| Govinda     | 54 M | NA | N      | 82.2 | 4.7 | 81   | 141   |
| Polachi     | 53 F | NA | N      | 64.4 | 4.4 | 68.8 | 128   |
| Rani        | 56 F | NA | N      | 72.6 | 4.5 | 77.4 | 148   |
| Shakuntala  | 33 F | NA | N      | 78   | 4.6 | 77.2 | 106   |
| Indrani     | 32 F | NA | N      | 75   | 4.6 | 71.7 | 121   |
| Subbammal   | 31 F | NA | N      | 68   | 4.8 | 83.2 | 129   |
| Anusuya     | 56 F | NA | N      | 80   | 5   | 67.4 | 138   |
| Kamakshi    | 42 F | NA | N      | 66   | 5.1 | 78.5 | 146   |
| Sarada      | 43 F | NA | N      | 66   | 3.9 | 77.4 | 152   |
| Rasathi     | 44 F | NA | N      | 67   | 3.7 | 79.2 | 141   |
| Neela       | 43 F | NA | N      | 66   | 3.8 | 74.3 | 121.6 |

## INDEX TO MASTER CHART

OP/IP NO. = OUTPATIENT / INPATIENT NUMBER

SEX:        F= FEMALE        M=MALE

N= NORMAL

DM= DIABETES MELLITUS

NPDR= NONPROLIFERATIVE

### DIABETIC RETINOPATHY

PDR= PROLIFERATIVE DIABETIC RETINOPATHY

FBS= FASTING BLOOD SUGAR

HbA1c= GLYCOSYLATED HAEMOGLOBIN

TGL= TOTAL TRIGLYCERIDES

TC= TOTAL CHOLESTEROL

HDL = HIGH DENSITY LIPOPROTEIN

LDL = LOW DENSITY LIPOPROTEIN

## ABBREVIATIONS

DM: DIBETES MELLITUS

DR: DIABETIC RETINOPATHY

NPDR: NONPROLIFERATIVE

DIABETIC RETINOPATHY

FBS: FASTING BLOOD SUGAR

HbA1c: GLYCOSYLATED HAEMOGLOBIN

TGL: TOTAL TRIGLYCERIDES

TC : TOTAL CHOLESTEROL

HDL : HIGH DENSITY LIPOPROTEIN

LDL : LOW DENSITY LIPOPROTEIN

**LIST OF SOME OPERATIONS PERFORMED DURING THE COURSE OF STUDY**

| Sl. No. | Name         | Age | Sex | OP/IP NO. | Diagnosis                          | Date of Surgery | Type of Surgery              |
|---------|--------------|-----|-----|-----------|------------------------------------|-----------------|------------------------------|
| 1.      | Thangavel    | 60  | M   | 68034     | RE- MC, LE-IMC                     | 23.08.06        | RE-ECCEwith PCIOL            |
| 2.      | Krishnammal  | 57  | F   | 69034     | LE- MC                             | 20.09.06        | LE-ECCEwith PCIOL            |
| 3.      | Chinnaraj    | 65  | M   | 406787    | LE-MC                              | 27.09.06        | LE-ECCEwith PCIOL            |
| 4.      | Vadivu       | 40  | F   | 402253    | RE-MC LE-IMC                       | 11.10.06        | RE-ECCEwithPCIOL             |
| 5.      | Pathu        | 55  | M   | 69887     | LE-MC                              | 18.10.06        | LE-ECCEwithPCIOL             |
| 6.      | Krishnan     | 54  | M   | 407503    | BE-IMC                             | 25.10.06        | BE-ECCEwithPCIOL             |
| 7.      | Rani         | 59  | F   | 16651     | RE-MC LE-IMC                       | 08.03.07        | RE-ECCEwithPCIOL             |
| 8.      | Lakshmi      | 65  | F   | 15725     | RE-HMC<br>LE-IMC                   | 15.03.07        | RE-ECCEwithPCIOL             |
| 9.      | Ramu         | 66  | M   | 15999     | LE-IMC                             | 22.03.07        | LE-ECCEwithPCIOL             |
| 10.     | Joseph       | 55  | M   | 22658     | LE- Sec.<br>Phacolytic<br>Glaucoma | 29.03.07        | LE-Lens Removal              |
| 11.     | Shanti       | 71  | M   | 32544     | LE-IMC                             | 05.04.07        | LE-ECCEwithPCIOL             |
| 12.     | Subramani    | 70  | M   | 28437     | BE-IMC                             | 19.04.07        | RE-ECCEwithPCIOL             |
| 13.     | Gajpati      | 60  | M   | 412151    | LE-IMC                             | 21.04.07        | LE-ECCEwithPCIOL             |
| 14.     | Ahmad        | 55  | M   | 412881    | RE-MC                              | 26.04.07        | RE-ECCEwithPCIOL             |
| 15.     | Pattamal     | 57  | F   | 413106    | BE-IMC                             | 04.05.07        | RE-ECCEwithPCIOL             |
| 16.     | Loganathan   | 65  | M   | 32288     | LE-MC                              | 07.05.07        | LE-ECCEwithPCIOL             |
| 17.     | Rajan        | 60  | M   | 27159     | RE-MC LE-IMC                       | 11.05.07        | RE-ECCEwithPCIOL             |
| 18.     | Kausalya     | 50  | F   | 31873     | BE-MC                              | 25.05.07        | RE-SICSwithPCIOL             |
| 19.     | Dhanalakshmi | 50  | F   | 31878     | LE-PSC                             | 28.05.07        | LE-SICSwithPCIOL             |
| 20.     | Periammal    | 70  | F   | 33645     | BE-MC                              | 01.06.07        | RE-ECCEwithPCIOL             |
| 21.     | Kausalya     | 60  | F   | 33702     | RE-MC                              | 04.06.07        | RE-SICSwithPCIOL             |
| 22.     | Pannaimmal   | 65  | F   | 417201    | BE-IMC                             | 08.06.07        | LE-SICS with PCIOL           |
| 23.     | Parsaran     | 70  | M   | 412714    | RE-Chronic<br>Dacryocystitis       | 24.09.07        | RE-<br>Dacryocystorhinostomy |
| 24.     | Saroja       | 65  | F   | 415022    | LE-Pterygium                       | 23.04.08        | LE- Pterygium excision       |
| 25.     | Vridhammal   | 60  | F   | 426519    | RE-IMC                             | 05.05.08        | RE- SICS with PCIOL          |